TG Therapeutics Inc (STU:NKB2)
€ 15.344 -0.116 (-0.75%) Market Cap: 2.33 Bil Enterprise Value: 2.24 Bil PE Ratio: 74.14 PB Ratio: 15.74 GF Score: 73/100

TG Therapeutics, Inc. - Special Call Transcript

Feb 28, 2019 / 01:30PM GMT
Release Date Price: €4.5 (+5.14%)
Operator

Greetings, and welcome to the TG Therapeutics UNITY-NHL trial update call. (Operator Instructions) Please note this conference is being recorded. I would now like to turn the conference over to your host today Ms. Jenna Bosco, Senior Vice President of Corporate Communications. Please go ahead, Ms. Bosco.

Jenna Bosco
TG Therapeutics, Inc. - VP of IR & Senior VP of Corporate Communications

Thank you. Good morning, and welcome to our conference call regarding the positive outcome from the marginal zone lymphoma cohort of the UNITY-NHL trial. I'm Jenna Bosco, TG's Senior Vice President of Corporate Communications, and I welcome you all to our call today.

Following our safe harbor statement, Michael Weiss, the company's Executive Chairman and Chief Executive Officer will provide an update regarding the UNITY-NHL news announced this morning as well as offer a brief update on the company's overall standing.

Before we begin, I would like to remind everyone that various remarks that we make about our future expectations, plans and prospects

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot